Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
AstraZeneca